ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Eisai-Biogen Alzheimer's drug off to slow US start amid controversy

Major hospitals steer clear as questions persist about effectiveness

Biogen reported an unexpectedly low $1.6 million in sales of aducanumab through the end of June.   © Reuters

NEW YORK/TOKYO -- The new Alzheimer's disease treatment developed by Tokyo-based Eisai and American partner Biogen has divided the U.S. medical community since its controversial approval in June, leading to slow initial sales for a drug viewed as a potential blockbuster.

Early uptake of aducanumab has been "a bit slower than what we assumed," Biogen CEO Michel Vounatsos said on an earnings call in July, about a month after approval.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more